Sotagliflozin: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Sotagliflozin. Educational only — not medical advice.
Labeled uses
INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors
Source: FDA labeling via NIH DailyMed (set 1a46614e…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.